GO
Loading...

Regeneron Pharmaceuticals Inc

More

  • March 27- Ohr Pharmaceutical Inc said its experimental eye drug failed the main goal in a mid-stage study as a combination therapy, sending the company's shares plunging 64 percent in premarket trading on Friday. The study tested the eye-drop solution, OHR-102, in combination with Roche Holding AG's injectable eye drug Lucentis, in patients with the wet...

  • March 23- Pfizer Inc and Eli Lilly and Co will resume a late-stage study testing their pain drug tanezumab after the U.S. Food and Drug Administration lifted a partial hold on it. Pfizer expects to receive a $200 million upfront payment from Lilly as a result of the development, the companies said on Monday. In 2013, Pfizer forged a deal with Lilly to jointly develop...

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • Cramer Remix: Oil news you've been waiting for Wednesday, 18 Mar 2015 | 7:34 PM ET
    Jim Cramer on Mad Money.

    You’ve been waiting months for the answer on oil, “Mad Money” host Jim Cramer’s got the answer.

  • Cramer: This sector has tons of hidden opportunity Monday, 16 Mar 2015 | 6:17 PM ET
    Biotech

    Jim Cramer is seeing an unusual trend in the market lately, which has set these stocks on fire.

  • New cholesterol drugs cut heart attack risk in half Monday, 16 Mar 2015 | 8:44 AM ET
    Amgen building in South San Francisco, California.

    Studies of a new class of cholesterol-lowering drugs signal that they can reduce by half the risk of heart attack.

  • An analysis of about 4,500 patients who stayed on treatment for nearly a year after completing earlier trials of Amgen Inc's Repatha, also known as evolocumab, found that 0.95 percent of those given the drug and standard therapy suffered a cardiovascular event, compared with 2.18 percent of the group on standard treatment, which ranged from diet changes to...

  • An analysis of about 4,500 patients who continued treatment for nearly a year after completing earlier trials of Amgen Inc's Repatha, also known as evolocumab, found that 0.95 percent of patients given the drug and standard therapy suffered a cardiovascular event, compared with 2.18 percent of the group receiving standard treatment, which ranged from...

  • Cramer's Top 10 performers from the past 10 years Friday, 13 Mar 2015 | 6:56 PM ET
    Netflix

    Jim Cramer put his research hat on and found the Top 10 performers in the past decade.

  • Cramer's game plan: Biggest fear on the dollar Friday, 13 Mar 2015 | 6:11 PM ET
    A man walks past Petrobras headquarters, Brazil's state-run oil company, March 9, 2015, in Rio de Janeiro.

    Jim Cramer sees one company out there that could be big trouble if the U.S. dollar keeps strengthening.

  • These cholesterol drugs stocks are poised to move Friday, 13 Mar 2015 | 3:33 PM ET
    Surgeons performing operation

    Here are the stocks to watch heading out of this weekend's American College of Cardiology conference in San Diego.

  • Lightning Round: Good chance this is downgraded Thursday, 12 Mar 2015 | 8:07 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer Remix: An Apple anniversary surprise Thursday, 12 Mar 2015 | 8:03 PM ET
    Jim Cramer speaks with Apple Inc. CEO Tim Cook on the 10th Anniversary of Mad Money.

    Apple CEO Tim Cook gives “Mad Money” host Jim Cramer the surprise of his career for his big 10th Anniversary show

  • Cramer's first CEO guest, 10 years later Thursday, 12 Mar 2015 | 12:59 AM ET
    Leonard Schliefer, CEO of Regeneron.

    Jim Cramer sits down with the first CEO guest of "Mad Money" a decade later. Find out where they are today.

  • What!?! Specialty drug spending jumps 31% Tuesday, 10 Mar 2015 | 8:53 AM ET
    Prescription drugs

    Spending on prescription drugs in the U.S. rose 13.1% in 2014, the biggest increase in more than a decade, according a report from Express Scripts.

  • Cramer Remix: Oil prices could hurt this stock Monday, 9 Mar 2015 | 7:31 PM ET
    Jim Cramer on Mad Money.

    “Mad Money” host Jim Cramer is raising flags when it comes to this stock.

  • Cramer's guide to the best stocks in a bear market Wednesday, 4 Mar 2015 | 6:34 PM ET

    Jim Cramer predicted bearish days ahead for March. But that doesn't mean you can't make money! Cramer gives his bear market survival guide of stocks.

  • Lightning Round: This group goes higher tomorrow Wednesday, 25 Feb 2015 | 7:29 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer Remix: Where's the Nasdaq bubble? Monday, 23 Feb 2015 | 7:02 PM ET
    Jim Cramer on the set of Mad Money

    As Apple hits new highs, "Mad Money" host Jim Cramer is betting on it to lift the Nasdaq.